Liquidia (LQDA) General Counsel Russell Sells $390K of Stock

Schundler Russell, General Counsel at Liquidia Corporation (LQDA), sold 13,692 shares on October 12, 2026. The sale was valued at approximately $389,948, with the shares sold at a price of $28.48 each. This transaction was planned in advance.

Inside Schundler Russell's Trade

Russell's sale of 13,692 shares represents a significant transaction for an insider. The sale was executed at $28.48 per share, and the total value of the sale was around $389,948. This move shows Russell's decision to reduce his stake in the company.

Other Institutional Activity in Liquidia Corporation

Blackrock Inc. grew its holdings by 5,299,329 shares, ending with 10,788,586 shares worth about $370.6 million. Vanguard Capital Management LLC added 212,206 shares, bringing its total to 3,139,183 shares valued at approximately $107.8 million. Farallon Capital Management LLC reduced its holdings by 290,837 shares, leaving it with 8,365,038 shares worth about $287.3 million. Caligan Partners, LP and Findell Capital Management LLC maintained their positions, holding 8,118,892 and 3,502,112 shares, respectively.

Liquidia Corporation Stock Down 2.9%

The stock recently traded at $33.77 as of October 16, 2026, which is 45.2% below its 50-day moving average of $61.62. It also sits 63.9% below its 52-week high of $93.61, indicating a challenging market position for the company. The shares are still above their 52-week low of $21.94 by about 53.9%.

Recent Earnings

Liquidia Corporation reported a trailing twelve-month revenue of approximately $450.9 million, with a net margin of 30.7%. The company has an impressive revenue growth rate of 1,842.7% year-over-year. Its next earnings report is set for November 3, 2026.

Insider Buying and Selling at Liquidia Corporation

On the same day as Russell's sale, several other insiders also sold shares. Dana Boyle, an Officer, sold 5,892 shares at $28.48, totaling about $167,804. Sanjeev Khindri, another Officer, sold 1,101 shares for about $31,356. Michael Kaseta, the Chief Operating Officer, sold 18,938 shares, valued at approximately $539,354. Jason Adair, also an Officer, sold 7,301 shares for about $207,932. All these transactions were not planned.

Analysts Set New Price Targets

On October 1, 2026, Raymond James downgraded Liquidia Corporation to an Outperform rating with a target of $53.00, down from $106.00. BTIG also downgraded the stock to Neutral on the same day. Needham maintained its Buy rating with a target of $72.00, while Wells Fargo downgraded to Equal-Weight with a target of $30.00 on October 2, 2026. The consensus from analysts currently recommends a Buy with a mean target price of $54.38 based on eight opinions.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company based in Morrisville, NC. It focuses on developing treatments for rare cardiopulmonary diseases, with its lead product candidate being YUTREPIA, a formulation for pulmonary arterial hypertension. This insider sale comes as the company navigates a challenging market backdrop.

Bottom Line

Investors should keep an eye on Liquidia's upcoming earnings report on November 3, 2026, and further insider transactions. The recent insider sales could signal shifts in management's outlook on the company's performance.